Ovarian cancer is the second most common gynecological malignancy, affects approximately 225,000 women worldwide, and remains the leading cause of cancer-related deaths in women [ 1 ]. Approximately 20% of ovarian cancer cases are hereditary …
verfasst von:
In Hee Lee, Soo Jung Lee, Juhyung Kim, Yoon Hee Lee, Gun Oh Chong, Jong Mi Kim, Juhun Lee, Nan Young Lee, Seo Young Park, Dea Gy Hong, Yee Soo Chae
Chemotherapy-induced alopecia (CIA), a side effect occurring after the administration of cytotoxic anticancer drugs, significantly reduces the quality of life for patients with cancer [ 1 ]. Approximately half of the patients with cancer have …
The phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) pathway regulates cell proliferation, growth, and survival, and is frequently dysregulated in cancer [ 1 , 2 ]. AKT, expressed in three isoforms (AKT1–3), is a central node in …
verfasst von:
Claire Miller, Roberto Sommavilla, Cindy L. O’Bryant, Minal Barve, Afshin Dowlati, Jason J. Luke, Mahmuda Khatun, Thomas Morris, Marie Cullberg
Lung cancer is the second most common primary malignant tumor worldwide and the leading cause of cancer-related mortality according to the most recent statistics provided by the International Agency for Research on Cancer (IARC) [ 1 ]. The …
verfasst von:
Xianping Xu, Yu Liu, Qiang Gong, Le Ma, Wei Wei, Linqiong Zhao, Zhibin Luo
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used as the standard treatment for EGFR -mutation-positive non-small cell lung cancer (NSCLC) [ 1 ], and can prolong both progression-free survival (PFS) and overall …
The global incidence rate and mortality of head and neck squamous cell carcinoma (HNSCC) is on the rise [ 1 ]. For patients with advanced tumors, chemotherapy is the first-line treatment, as recommended in the current clinical guidelines [ 2 ].
A postoperative chemotherapy regimen including a fluoropyrimidine and oxaliplatin is the standard of care for patients with stage III or high-risk stage II colon cancer [ 1 ]. Among clinical trial participants with stage II–III colon cancer …
verfasst von:
Justin C. Brown, Jeffrey A. Meyerhardt, Shengping Yang, Bette J. Caan
Non-small cell lung cancer (NSCLC), accounting for 85–90% of all lung cancer cases, is a leading cause of cancer death worldwide [ 1 ]. Anaplastic lymphoma kinase (ALK) gene rearrangement is one of common oncogenic mutations in lung cancer, which …
Pancreatic adenocarcinoma (PAAD) is a highly malignant tumor with a rising incidence, and despite numerous efforts to improve therapeutic outcomes, its prognosis remains poor, with a 5-year overall survival (OS) of 9% [ 1 , 2 ]. Characterized by …
Belinostat was approved in 2014 for the treatment of relapsed or refractory peripheral T-cell lymphoma, however, there was insufficient data to recommend a dose in patients with moderate to severe hepatic impairment. The purpose of this analysis …
verfasst von:
Allison Dunn, Naoko Takebe, Alice Chen, Shivaani Kummar, Richard Piekarz, Brian Kiesel, Nancy Moore, James Doroshow, Jan H. Beumer, Jogarao V. S. Gobburu
High-dose methotrexate (MTX) therapy (HD-MTX) is the standard treatment for several malignant tumors including acute lymphatic leukemia, malignant lymphoma, and osteosarcoma [ 1 – 6 ]. The risk of HD-MTX therapy depends on the administration …
Regorafenib is an orally administered, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI) that inhibits the activity of various protein kinases involved in the regulation of tumor angiogenesis (vascular endothelial growth factor …
Breast cancer (BC) is one of the most common malignant disorders in females. BC accounts for nearly 30% of all new cancer cases and > 14% of cancer-related deaths among women worldwide [ 1 ]. As a subpopulation of cancer cells, breast cancer stem …
verfasst von:
Wei Zheng, Wei Peng, Fuyong Qian, Mingshuai Zhang, Bofeng Duan, Zhifeng Fan, Yi Xie, Xiaoying Fu
Therapeutic antibodies play a crucial role in cancer treatment. Inter-individual variability is reported in the pharmacokinetics of therapeutic antibodies [ 1 ]. Anti-drug antibody formation can contribute to the high inter-individual variability …
Docetaxel is a taxane chemotherapeutic agent that is widely used in the clinic as single agent or in combination with other cytotoxic drugs for the treatment of a broad range of cancers, such as breast cancer, non-small cell lung cancer and …
verfasst von:
Nancy H.C. Loos, Viët Bui, Daniëlle H. de Jong, Maria C. Lebre, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
Malignant tumors are consistently among the top five causes of death in China, with rates increasing since 2000 [ 1 ]. In 2022, there were approximately 4,820,000 new cancer cases and 3,210,000 cancer deaths in China, with lung cancer being the …
verfasst von:
Colby S. Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan, Qi Liu, Yih-Wen Chen, Benjamin Wu, Qiong Wu, Xian Wang
Capecitabine (CAP) is one of the fluoropyrimidine deoxynucleoside carbamates, which can be converted to 5-fluorouracil (5-FU) by thymine deoxynucleoside phosphorylase (dThdPase) to exert antitumor effects. The purpose of this study is to compare …
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm associated with the specific chromosomal translocation in chromosomes 9 and 22, which is known as the Philadelphia chromosome (Ph). Around 95% of the patients with CML are detected …
verfasst von:
Jaya Shree Dilli Batcha, Vikram Gota, Saikumar Matcha, Arun Prasath Raju, Mahadev Rao, Karthik S. Udupa, Surulivelrajan Mallayasamy
